Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 2/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9920270 | 0.86 | CSF1R (0.48) | CSF1RPDE4BSYKNPC1PKM | |
| SCHEMBL9923075 | 0.85 | CSF1R (0.47) | CSF1RPDE4BSYKNPC1PKM | |
| SCHEMBL9923333 | 0.84 | PDE4B (0.47) | CSF1RPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL12875308 | 0.81 | CSF1R (0.44) | CSF1RPDE4BSYKCLCN2PDE4A | |
| SCHEMBL9923076 | 0.80 | CSNK2A1 (0.36) | LMNAKMT2APABPC1 | |
| SCHEMBL9923398 | 0.78 | JAK3 (0.47) | CSF1RLMNA | |
| SCHEMBL9920282 | 0.77 | JAK2 (0.58) | NPC1RAB9A | |
| SCHEMBL9920277 | 0.74 | JAK3 (0.50) | CSF1R | |
| SCHEMBL9923331 | 0.74 | JAK1 (0.61) | — | |
| SCHEMBL9923438 | 0.72 | JAK3 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | CSF1R 315/4885PDE4B 2524/4885SYK 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.